India’s vaccine policy needs a rethink as disease patterns and living standards change

As debates unfold globally over changes to childhood vaccination policies, including recent revisions in the United States, it is an appropriate moment for India to re-examine its own immunisation framework not in response to those developments, but because India’s economic growth, sanitation gains and disease profile are evolving rapidly .

India’s Universal Immunisation Programme (UIP) remains one of the country’s most successful public-health interventions, credited with dramatically reducing infant and child mortality over the past four decades. Built around the principle of preventing death and lifelong disability at population scale , the programme prioritised diseases that once posed the gravest risks to Indian children.

That strategy remains fundamentally sound . But the epidemiological assumptions that shaped the UIP are no longer static.

The UIP currently provides free, universal vaccination against diseases such as tuberculosis, polio, diphtheria, tetanus, pertussis, measles-rubella, hepatitis B, pneumococcal disease and rotavirus . These were chosen because they caused widespread mortality, severe disability or long-term health consequences , particularly in early childhood.

At the same time, several vaccines that are widely recommended by paediatricians including those for hepatitis A, chickenpox (varicella), influenza, mumps, meningococcal disease and human papillomavirus (HPV) remain outside the government programme , largely accessible only through private healthcare.

This exclusion is often misread as reluctance or scepticism . In reality, it reflects cost-effectiveness and disease-burden calculations rooted in India’s earlier public-health reality. Hepatitis A , for instance, historically infected most children early in life, producing mild illness and lifelong natural immunity . Chickenpox and mumps were typically self-limiting childhood diseases with low hospitalisation rates. Influenza , requiring annual vaccination, carried high recurring costs relative to its paediatric mortality impact.

However, that reality is changing .

In many urban and semi-urban areas , improvements in water quality, sanitation and housing have delayed exposure to infections such as hepatitis A. While this is a marker of progress, it also means more people now encounter the virus later in life , when illness tends to be more severe, prolonged and sometimes life-threatening . Clinicians in large cities increasingly report adult hepatitis A hospitalisations, a pattern rarely seen a generation ago.

A similar transition is emerging with chickenpox , where delayed infection raises complication risks, and with HPV-related cancers , which now represent a significant public-health burden . India continues to record one of the world’s highest cervical cancer caseloads , despite the availability of effective vaccines.

These shifts suggest that India’s immunisation strategy must gradually evolve from a pure early-childhood survival model to a life-course prevention approach . This does not require the wholesale expansion of the UIP overnight, but it does demand clear policy signalling aligned with changing risk profiles.

Public-health experts increasingly argue for a tiered vaccination framework . Hepatitis A vaccination , for example, could be prioritised in cleaner, urban and higher-income neighbourhoods where natural immunity is declining. HPV vaccination could be scaled nationally through school-based adolescent programmes , rather than infant schedules. Seasonal influenza vaccination may remain targeted rather than universal, but should feature more prominently in public messaging for vulnerable groups.

Crucially, such changes would represent an evolution of the UIP, not a dilution of its principles . India’s success has rested on clarity and authority : vaccines included in the programme are safe, necessary and strongly recommended . That clarity should not be weakened by framing immunisation as a matter of personal preference.

While other countries may revise vaccine policies for reasons tied to trust, choice or political context , India’s reassessment is driven by its own progress . As incomes rise and disease patterns shift, preventive healthcare expectations will also change .

Periodic, data-driven reviews of the UIP grounded in epidemiology rather than ideology will be essential to ensure that India’s immunisation strategy continues to protect not only against the diseases of the past, but also those emerging from the country’s economic and social transformation .